The PPARs: From Orphan Receptors to Drug Discovery
The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTThe PPARs: From Orphan Receptors to Drug Discovery†Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach, and Brad R. HenkeView Author Information Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709 Cite this: J. Med. Chem. 2000, 43, 4, 527–550Publication Date (Web):February 24, 2000Publication History Received8 November 1999Published online24 February 2000Published inissue 1 February 2000https://pubs.acs.org/doi/10.1021/jm990554ghttps://doi.org/10.1021/jm990554greview-articleACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views6740Altmetric-Citations1452LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Agonists,Ligands,Lipids,Receptors,Rodent models Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is an extremely selective PPARα agonist (subtype selectivity > 5000-fold for PPARγ and > 11,000-fold for PPARδ, respectively) [49, 50].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
In the citing paper
“The PPARα activation by pemafibrate was > 2500 times stronger than fenofibric acid, the active form of fenofibrate.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
Citations
Cites
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Self-citationA Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Research works printed but not linked: 124
- Lichtenstein A. H., 1998, Nutr. Rev., 56, S28
- Harris M. I., 1998, Diabetes Care, 21, 524
- Howard B. V., 1995, Int. Congr. Ser.
- Barzilai N., 1999, J. Gerontol., Ser. A, 54, B96
- Lichtenstein A. H., 1999, Nutr. Rev., 57, 14
- Jump D. B., 1999, Annu. Rev. Nutr., 19, 90
- Mangelsdorf D. J., 1995, Cell, 83, 850
- A, 1999, Cell, 97, 163
- Xu H. E., 1999, Mol. Cell, 3, 403
- Hu E., 1996, Science, 274, 2103
- Zhang B., 1996, J. Biol. Chem., 271, 31774
- Adams M., 1997, J. Biol. Chem., 272, 5132
- Camp H. S., 1999, Endocrinology, 140, 397
- Juge-Aubry C. E., 1999, J. Biol. Chem., 274, 10510
- McDonnell D. P., 1993, Bio/Technology, 11, 1261
- Lehmann J. M., 1995, J. Biol. Chem., 270, 12956
- Xu L., 1999, Curr. Opin. Genet. Dev., 9, 147
- Zhu Y., 1996, Gene Expression, 6, 195
- Dowell P., 1997, J. Biol. Chem., 272, 33443
- Zhu Y., 1997, J. Biol. Chem., 272, 25506
- Yuan C.-X., 1998, Proc. Natl. Acad. Sci. U.S.A., 95, 7944
- Treuter E., 1998, Mol. Endocrinol., 12, 881, 10.1210/mend.12.6.0123 · doi:10.1210/mend.12.6.0123 · Paper page
- Krey G., 1997, Mol. Endocrinol., 11, 791, 10.1210/mend.11.6.0007 · DOI · Paper page
- Zhou G., 1998, Mol. Endocrinol., 12, 1604, 10.1210/mend.12.10.0176 · doi:10.1210/mend.12.10.0176 · Paper page
- Berger J., 1996, Endocrinology, 137, 4195
- Young P. W., 1998, J. Pharmacol. Exp. Ther., 284, 759
- Bell A. R., 1998, Biochem. J., 332, 693
- Heuvel J. P. V, 1999, Toxicol. Sci., 47, 8
- Palmer C. N. A., 1998, Mol. Pharmacol., 53, 22
- Gervois P., 1999, Mol. Endocrinol., 13, 1549
- Gaw A., 1994, Handb. Exp. Pharmacol., 109, 348
- Brown P. J., 1997, Synthesis, 778, 782
- Brown P. J., 1999, J. Med. Chem., 42, 3788
- Forman B. M., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 4317
- Yu K., 1995, J. Biol. Chem., 270, 23983
- Palmer C. N. A., 1994, J. Biol. Chem., 269, 18089
- Lee S. S.-T., 1995, Mol. Cell. Biol., 15, 3022
- Peters J. M., 1997, J. Biol. Chem., 272, 27312
- Gaw A., 1999, Lipoproteins Health Dis., 1145, 1160
- Ross S. D., 1999, Arch. Intern. Med., 159, 1802
- Oliver M. F., 1984, Lancet, 2, 604
- Rutolo G., 1998, J. Am. Coll. Cardiol., 32, 1656
- Libby P., 1999, Mol. Basis Cardiovasc. Dis., 349, 366
- Spencer N. F. L., 1997, Int. Immunol., 9, 1588
- Delerive P., 1999, J. Biol. Chem., 45, 32054
- Vazquez M., 1995, Br. J. Pharmacol., 116, 2075
- Jacobsson A., 1985, J. Biol. Chem., 260, 16254
- Krook A., 1998, Diabetes, 47, 1531
- Ruyter B., 1997, Biochim. Biophys. Acta, 1348, 338
- Zhu Y., 1993, J. Biol. Chem., 268, 26820
- Greene M. E., 1995, Gene Expression, 4, 299
- Chawla A., 1994, Endocrinology, 135, 800, 10.1210/endo.135.2.8033830 · doi:10.1210/endo.135.2.8033830 · Paper page
- Saladin R., 1999, Cell Growth Differ., 10, 48
- Martin G., 1997, J. Biol. Chem., 272, 28217
- Hofmann C., 1994, Endocrinology, 134, 270, 10.1210/endo.134.1.8275942 · DOI · Paper page
- Tai T.-A. C., 1996, J. Biol. Chem., 271, 29914
- Kelly L. J., 1998, Endocrinology, 139, 4927
- Hulin B., 1996, Curr. Pharm. Des., 2, 102
- Kletzien R. F., 1992, Mol. Pharmacol., 41, 398
- Ibrahimi A., 1994, Mol. Pharmacol., 46, 1076
- Harris P. K. W., 1994, Mol. Pharmacol., 45, 445
- Willson T. M., 1996, J. Med. Chem., 39, 668
- Ide T., 1998, Diabetes Front, 9, 346
- Shinkai H., 1998, J. Med. Chem., 41, 1933
- Reginato M. J., 1998, J. Biol. Chem., 273, 32684
- Reddy K. A., 1999, J. Med. Chem., 42, 3278
- Sohda T., 1984, Chem. Pharm. Bull., 32, 4465
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2126
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2130
- Henke B. R., 1998, Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem
- Collins J. L., 1998, Structure−activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem
- Cobb J. E., 1998, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure−activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5069
- Lehmann J. M., 1997, J. Biol. Chem., 272, 3410
- Verrando P., 1981, Biochim. Biophys. Acta, 663, 265
- Negishi M., 1995, J. Lipid Mediators Cell Signalling, 12, 448
- Narumiya S., 1991, Dev. Oncol., 67, 448
- Ikeda H., 1990, Arzneim.-Forsch., 40, 162
- Horikoshi H., 1994, Annu. Rep. Sankyo Res. Lab., 46, 57
- Prigeon R. L., 1998, J. Clin. Endocrinol. Metab., 83, 823
- Fonseca V. A., 1998, J. Clin. Endocrinol. Metab., 83, 3176
- Spencer C. M., 1997, Drugs, 54, 101
- Kumar S., 1996, Diabetologia, 39, 709
- Gimble J. M., 1996, Mol. Pharmacol., 50, 1094
- Jones S. A., 2000, Mol. Endocrinol., 14, 39, 10.1210/mend.14.1.0409 · doi:10.1210/mend.14.1.0409 · Paper page
- Blumberg B., 1998, Genes Dev., 12, 3205
- Ramachandran V., 1999, Drug Metab. Dispos., 27, 1199
- Yamazaki H., 1999, Drug Metab. Dispos., 27, 1266
- Pumford N. R., 1997, Annu. Rev. Pharmacol. Toxicol., 37, 117
- Miller V. A., 1997, J. Clin. Oncol., 15, 795
- Rizvi N. A., 1999, Clin. Cancer Res., 5, 1664
- Vidal-Puig A. J., 1997, J. Clin. Invest., 99, 2422
- Park K. S., 1997, Diabetes, 46, 1234
- Wu Z., 1998, J. Clin. Invest., 101, 32
- Sreenan S., 1999, Am. J. Physiol., 276, E1129
- Miles P. D. G., 1997, Diabetes, 46, 1683
- Yen C.-J., 1997, Biochem. Biophys. Res. Commun., 241, 274
- Deeb S. S., 1998, Nat. Genet., 20, 287
- Valve R., 1999, J. Clin. Endocrinol. Metab., 84, 3712
- Mori Y., 1998, Biochem. Biophys. Res. Commun., 251, 198
- Ek J., 1999, Diabetologia, 42, 895
- Hamann A., 1999, Eur. J. Endocrinol., 141, 92
- Girard J, 1997, Diabetes Metab., 23, 24
- McKeigue P., 1997, Handb. Hypertens., 17, 934
- Dubey R. K., 1993, Am. J. Physiol., 265, R732
- Zhang H. Y., 1994, Hypertension, 24, 110
- Morikang E., 1997, Am. J. Hypertens., 10, 446
- Law R. E., 1996, J. Clin. Invest., 98, 1905
- Kotchen T. A., 1996, Am. J. Physiol., 270, R666
- Zhang F., 1994, Hypertension, 24, 175
- Su C. G., 1999, J. Clin. Invest., 104, 389
- Ehrmann D. A., 1997, J. Clin. Endocrinol. Metab., 82, 2116
- Minamikawa J., 1998, J. Clin. Endocrinol. Metab., 83, 1820
- Suh N., 1999, Cancer Res., 59, 5673
- Lefebvre A.-M., 1998, Nat. Med., 4, 1057
- Schmidt A., 1992, Mol. Endocrinol., 6, 1641
- Amri E.-Z., 1995, J. Biol. Chem., 270, 2371
- Brooks C. D. W., 1996, J. Med. Chem., 39, 2654
- Brun R. P., 1996, Genes Dev., 10, 984
- Lim H., 1999, Genes Dev., 13, 1574
- He T.-C., 1999, Cell, 99, 345
- Cobb J., 1998, Annu. Rep. Med. Chem., 33, 222
- Sliskovic D. R., 1999, Annu. Rep. Med. Chem., 34, 110
- Belch J. J. F., 1998, Proc. Nutr. Soc., 57, 569
- Woutersen R. A., 1999, Mutat. Res., 443, 127
Cited by
Items 901–1,000 of 1,003
Clofibrate inhibits the umami-savory taste of glutamate
Kochem, M., & Breslin, P. A. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172534 · Cited by 28
Investigation of the lipophilic behaviour of some thiazolidinediones
Giaginis, C., Theocharis, S. E., & Tsantili‐Kakoulidou, A. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.07.013 · Cited by 28
Convergence of lipid homeostasis through liver X and thyroid hormone receptors
Berkenstam, A. L., Färnegårdh, M., & Gustafsson, J.-Α. (2004) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.05.005 · Cited by 30
Grommes, C., Landreth, G. E., Schlegel, U. S., & Heneka, M. T. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078972 · Cited by 28
“Nonthiazolidinedione tyrosine-based PPAR ligands have been described as potent and selective PPAR agonists (Willson et al., 2000) and GW7845 as one of the nonthiazolidinedione tyrosine-based PPAR ligands that showed antineoplastic effects in human breast cancer (Liu et al., 2003) and rat mammalian…”
BackgroundInfluentialRegulation of Translational Efficiency by Disparate 5′‐UTRs of PPARγ Splice Variants
McClelland, S., Shrivastava, R., & Medh, J. D. (2009) · PPAR Research · doi:10.1155/2009/193413 · Cited by 28
“Peroxisome proliferators-activated receptors (PPAR) are a family of nuclear receptors associated with cellular differentiation, and with the regulation of carbohydrate and lipid metabolism [1, 2].”
BackgroundSynthesis and biological activity of l-tyrosine-based PPARγ agonists with reduced molecular weight
Liu, K. G., Lambert, M. H., Ayscue, A. H., Henke, B. R., Leesnitzer, L. M., Oliver, W. R., Plunket, K. D., Xu, H. E., Sternbach, D. D., & Willson, T. M. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00649-7 · Cited by 28
Self-citationHelledie, T., Jørgensen, C., Antonius, M., Krogsdam, A., Kratchmarova, I., Kristiansen, K., & Mandrup, S. (2002) · Springer eBooks · doi:10.1007/978-1-4419-9270-3_20 · Cited by 28
Blocking the Peroxisome Proliferator‐Activated Receptor (PPAR): An Overview
Ammazzalorso, A., Filippis, B. D., Giampietro, L., & Amoroso, R. (2013) · ChemMedChem · doi:10.1002/cmdc.201300250 · Cited by 27
Glitazonas e síndrome metabólica: mecanismos de ação, fisiopatologia e indicações terapêuticas
Gomes, M. B. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200013 · Cited by 40
Wang, C., Fang, C., Wang, C., Jin, C., Qian, M., & Jin, Y. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00424 · Cited by 28
Rasouli, N., Kern, P. A., Elbein, S. C., Sharma, N., & Das, S. K. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328352a72e · Cited by 27
Yadav, P., Kumar, P., Mukesh, M., Kataria, R. S., Yadav, A., Mohanty, A. K., & Mishra, B. P. (2015) · Research in Veterinary Science · doi:10.1016/j.rvsc.2015.01.003 · Cited by 27
Bernardo, A., Simone, R. D., Nuccio, C. D., Visentin, S., & Minghetti, L. (2013) · Biological Chemistry · doi:10.1515/hsz-2013-0152 · Cited by 28
“The three members of the PPAR family (PPAR-α, PPAR-β/δ and PPAR-γ) share a high homology and a similar organization in five different functional domains, two of which – the DNA-binding domain and the ligand-binding domain (Figure 1A and B) – are highly conserved among species (Willson et al., 2000).”
Wagner, J. D., Shadoan, M. K., Zhang, L., Ward, G. M., Royer, L. J., Kavanagh, K., Francone, O. L., Auerbach, B. J., & Harwood, H. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166736 · Cited by 27
“…nuclear receptors that associate with key naturally occurring lipid molecules and function as transcription factors in the regulation of carbohydrate and lipid metabolism, among other biological processes (Harwood and Hamanaka, 1998; Corton et al., 2000; Willson et al., 2000; Winegar et al., 2001).”
BackgroundMethodResultInfluentialRathore, P. K., Arathy, V., Attimarad, V. S., Kumar, P., & Roy, S. (2015) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2015.12.004 · Cited by 27
Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands and Their Therapeutic Utility
Henke, B. R. (2004) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(04)42001-3 · Cited by 29
Self-citationBarrera, G., Toaldo, C., Pizzimenti, S., Cerbone, A., Pettazzoni, P., Dianzani, M. U., & Ferretti, C. (2008) · PPAR Research · doi:10.1155/2008/524671 · Cited by 33
“Like PPARα, PPARβ/δ is activated by long chain fatty acids, including several polyunsaturated fatty acids and eicosanoids [3].”
BackgroundEffects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells
Cheon, C. W., Kim, D. H., Kim, D. H., Cho, Y. H., & Kim, J. H. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.310 · Cited by 27
“, and the ligands that activate PPAR-γ are currently being studied as a possible novel therapeutic modality [ 19 ,22-26]”
BackgroundMethodClinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors
Marschall, H., Wagner, M., Zollner, G., & Trauner, M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060133c · Cited by 30
Takano, M., Otsuka, F., Matsumoto, Y., Inagaki, K., Takeda, M., Nakamura, E., Tsukamoto, N., Miyoshi, T., Sada, K., & Makino, H. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.027 · Cited by 27
Joly, E. C., Roduit, R., Peyot, M., Habinowski, S. A., Ruderman, N. B., Witters, L. A., & Prentki, M. (2009) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00043.x · Cited by 27
“Peroxisome proliferator-activated receptor a (PPARa) belongs to a nuclear receptor family of ligand-activated transcription factors that bind fatty acids and their metabolites.(1) PPARa regulates the expression of genes of fatty acid metabolism.”
BackgroundDesign and synthesis of novel RXR-selective modulators with improved pharmacological profile
Michellys, P., Boehm, M. F., Chen, J., Grese, T. A., Karanewsky, D. S., Leibowitz, M. D., Liu, S., Mais, D. E., Mapes, C. M., Reifel-Miller, A. E., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.08.048 · Cited by 27
Gouni‐Berthold, I., Giannakidou, E., Müller‐Wieland, D., Faust, M., Kotzka, J., Berthold, H. K., & Krone, W. (2005) · Journal of Hypertension · doi:10.1097/00004872-200502000-00012 · Cited by 27
Shen, L., Zhang, Y., Wang, A., Sieber-McMaster, E. S., Chen, X., Pelton, P. D., Xu, J. Z., Yang, M., Zhu, P., Zhou, L., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.12.005 · Cited by 27
Moulin, D., Bianchi, A., Boyault, S., Sébillaud, S., Koufany, M., François, M., Netter, P., Jouzeau, J., & Terlain, B. L. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20868 · Cited by 27
“However, rosiglita-zone is one ligand that has a high affinity for PPAR (55), which was shown to modulate PPAR -dependent genes in experimental diabetes (56) and atherosclerosis (57).”
BackgroundPalka, J. A., Ościłowska, I., & Szoka, Ł. (2021) · Amino Acids · doi:10.1007/s00726-021-02968-y · Cited by 29
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists
Matin, A., Doddareddy, M. R., Gavande, N. S., Nammi, S., Groundwater, P. W., Roubin, R. H., & Hibbs, D. E. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.040 · Cited by 26
The PPAR‐Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects
Spinelli, S., O'Brien, J. J., Bancos, S., Lehmann, G. M., Springer, D. L., Blumberg, N., Francis, C. W., Taubman, M. B., & Phipps, R. P. (2007) · PPAR Research · doi:10.1155/2008/328172 · Cited by 29
“PPARγ is important in adipocyte differentiation, lipid storage, and glucose homeostasis, and has emerged as a key target for new antiinflammatory therapies [6, 90, 91].”
BackgroundXu, C., Wang, L., Liu, H., Zhou, X.-B., Cao, Y.-L., & Li, S. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00263.x · Cited by 26
Nie, F., Liang, Y., Xun, H., Sun, J. Y., He, F., & Ma, X. (2015) · Food & Function · doi:10.1039/c4fo00871e · Cited by 26
Rohatgi, A. K., & McGuire, D. K. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6093-z · Cited by 26
“The TZD target of action is the peroxisome proliferatoractivated (PPAR)-γ receptor, a nuclear hormone receptor superfamily of ligand-activated transcription factors that coordinately regulates gene transcription [6–8].”
BackgroundRestoration of C/EBPα in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis
Wu, Y. V., Okada, T., DeCarolis, P. L., Socci, N. D., O’Connor, R., Geha, R. C., Somberg, C. J., Antonescu, C. R., & Singer, S. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21917 · Cited by 28
Keil, S., Matter, H., Schönafinger, K., Glien, M., Mathieu, M., Marquette, J.-P., Michot, N., Haag‐Diergarten, S., Urmann, M., & Wendler, W. (2011) · ChemMedChem · doi:10.1002/cmdc.201100047 · Cited by 28
Hiep, N. T., Choi, Y., Kim, N., Hong, S. S., Hong, S., Hwang, B. Y., Lee, H.-J., Lee, S., Jang, D. S., & Lee, D. (2012) · Journal of Natural Products · doi:10.1021/np200955z · Cited by 26
Martin, S. J., & Prince, S. E. (2016) · Renal Failure · doi:10.1080/0886022x.2016.1184940 · Cited by 26
“It is further known that RXR dimerizes with LXR and FXR and causes the activation of many genes.(24) It has also been shown in many previous studies that vitamin B12 plays a major role in the metabolism of lipids through receptors such as cubilin.”
BackgroundKumar, K. S., Rao, A. L., & Rao, M. V. B. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00807 · Cited by 26
“These are also having drawbacks like hepatotoxicity [2], oedema, haematological toxicity and body weight gain problems [3].”
BackgroundVestergaard, H., Lund, S. A., & Pedersen, O. B. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00898.x · Cited by 26
Beneficial Effects of Pioglitazone on Left Ventricular Hypertrophy in Genetically Hypertensive Rats
Shinzato, T., Ohya, Y., Nakamoto, M., Ishida, A., & Takishita, S. (2007) · Hypertension Research · doi:10.1291/hypres.30.863 · Cited by 26
Chu, X., Li, X., Nishimura, K., Jisaka, M., Nagaya, T., Shono, F., & Yokota, K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.01.022 · Cited by 26
Seethala, R., Golla, R., Ma, Z., Zhang, H., O’Malley, K., Lippy, J., Cheng, L., Mookhtiar, K. A., Farrelly, D., Zhang, L., et al. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.01.022 · Cited by 26
Rathi, L., Kashaw, S. K., Dixit, A., Pandey, G., & Saxena, A. K. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.10.032 · Cited by 26
Pruimboom‐Brees, I., Haghpassand, M., Royer, L. J., Brees, D., Aldinger, C. E., Reagan, W. J., Singh, J., Kerlin, R. L., Kane, C. D., Bagley, S. W., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051110 · Cited by 29
Foreman, J. E., Sharma, A. K., Amin, S., Gonzalez, F. J., & Peters, J. M. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.07.006 · Cited by 27
“Indeed, fibrate drugs are PPARα ligands that effectively lower triglycerides [2;3], and thiazolidinediones are PPARγ agonists used to treat type II diabetes [4;5].”
Vansant, G., Pezzoli, P., Saiz, R., Birch, A., Duffy, C., Ferre, F., & Monforte, J. (2006) · International Journal of Toxicology · doi:10.1080/10915810600605690 · Cited by 26
Design, synthesis and evaluation of carbazole derivatives as PPARα/γ dual agonists and antioxidants
Kumar, R., Ramachandran, U., Srinivasan, K. K., Ramarao, P., Raichur, S., & Chakrabarti, R. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.018 · Cited by 26
Collin, M., Murch, O., & Thiemermann, C. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000206472.63040.6d · Cited by 26
“Since the identification of the first PPAR receptor in the mouse (3), three isoforms— designated PPAR- , PPAR- / , and PPAR- — have been cloned and characterized by their distinct expression patterns, different ligand-binding specificity, and metabolic functions (4).”
BackgroundShao, Y. Y., Wang, L., Hicks, D. G., Tarr, S. M., & Ballock, R. T. (2005) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2005.02.011 · Cited by 28
Xu, Y., Etgen, G. J., Broderick, C. L., Canada, E. J., Gonzalez, I., Lamar, J., Montrose‐Rafizadeh, C., Oldham, B. A., Osborne, J. J., Xie, C., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060617c · Cited by 26
Zhang, J., Fu, M., Zhao, L., & Chen, Y. E. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02401-4 · Cited by 26
Thiazolidinediones: A Pharmacological Overview
Owens, D. R. (2002) · Clinical Drug Investigation · doi:10.2165/00044011-200222080-00001 · Cited by 28
Emerging drugs for endometriosis
Guo, S.-W. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802548360 · Cited by 24
“(PPAR-g ) agonists and retinoid X receptor (RXR) ligands PPAR- γ is activated by fatty acid derivatives, thiazolidinediones (TZDs), and by certain NSAIDs [162,163] .”
BackgroundInfluentialSteroid Hormone Receptors and Signal Transduction Processes
Klinge, C. M. (2018) · Endocrinology · doi:10.1007/978-3-319-44675-2_9 · Cited by 26
Synthesis and evaluation of azaindole-α-alkyloxyphenylpropionic acid analogues as PPARα/γ agonists
Cai, Z., Feng, J., Guo, Y., Li, P., Shen, Z., Chu, F., & Guo, Z. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.09.040 · Cited by 25
Fang, I., Yang, C., & Yang, C. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400196 · Cited by 25
The synthesis of tethered ligand dimers for PPARγ–RXR protein heterodimers
Mohler, D. L., & Shen, G. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b600848h · Cited by 25
Characterization of New PPARγ Agonists: Benzimidazole Derivatives – the Importance of Position 2
Goebel, M., Staels, B., Unger, T., Kintscher, U., & Gust, R. (2009) · ChemMedChem · doi:10.1002/cmdc.200900067 · Cited by 25
Jinno, Y., Nakakuki, M., Sato, A., Kawano, H., Notsu, T., Mizuguchi, K., & Shimano, H. (2010) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2010.05.002 · Cited by 25
“The contribution of hepatic expression of PPARγ to plasma ALT was not significant.”
BackgroundInfluentialAmmazzalorso, A., Lellis, L. D., Florio, R., Bruno, I., Filippis, B. D., Fantacuzzi, M., Giampietro, L., Maccallini, C., Perconti, S., Verginelli, F., et al. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13026 · Cited by 26
Evaluation of Distance Metrics for Ligand‐Based Similarity Searching
Fechner, U., & Schneider, G. (2004) · ChemBioChem · doi:10.1002/cbic.200300812 · Cited by 25
PPAR Ligands for Cancer Chemoprevention
Yasui, Y., Kim, M.-H., & Tanaka, T. (2008) · PPAR Research · doi:10.1155/2008/548919 · Cited by 25
“The essential fatty acids (arachidonic acid, docosahexanoic acid, and eicosapentaenoic acid) as well as modified oxidized lipids (9-hydroxyoctadecanoic acid and 13-hydroxyoctadecanoic acid) bind to and activate PPARγ [5].”
BackgroundOshio, H., Abe, T., Onogawa, T., Ohtsuka, H., Sato, T., Ii, T., Fukase, K., Muto, M., Katayose, Y., Oikawa, M., et al. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2188-3 · Cited by 25
Asaki, T., Aoki, T., Hamamoto, T., Sugiyama, Y., Ohmachi, S., Kuwabara, K., Murakami, K., & Todo, M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.007 · Cited by 25
A combined ligand and structure based approach to design potent PPAR-alpha agonists
Dhoke, G. V., Gangwal, R. P., & Sangamwar, A. T. (2012) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2012.06.032 · Cited by 25
High content screening for nonclassical peroxisome proliferators
Sexton, J. Z., He, Q., Forsberg, L. J., & Brenman, J. E. (2010) · International Journal of High Throughput Screening · doi:10.2147/ijhts.s10547 · Cited by 26
PPARα and PPARγ Regulation of Liver and Adipose Proteins in Obese and Dyslipidemic Rodents
Lanne, B., Dahllöf, B., Lindahl, C., Ebefors, K., Kanmert, I., von Bahr, H., Miliotis, T., Nyström, A., Arnerup, G., Paulsons, I., et al. (2006) · Journal of Proteome Research · doi:10.1021/pr060004o · Cited by 25
Li, X., Yang, X., Xu, Y., Jiang, X., Li, X., Nan, F., & Tang, H. (2009) · Cell Research · doi:10.1038/cr.2009.53 · Cited by 25
Raval, P., Jain, M., Goswami, A., Basu, S., Gite, A., Godha, A. K., Pingali, H., Raval, S., Giri, S. R., Suthar, D., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.020 · Cited by 25
When analoging is not enough: scaffold discovery in medicinal chemistry
Zhao, H., & Akritopoulou‐Zanze, I. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903584874 · Cited by 25
“Although PPARs share substantial structural homology, pan-agonists have been challenging to design owing to the subtle differences among the binding pockets [34].”
BackgroundPalermo, F. A., Cocci, P., Mozzicafreddo, M., Arukwe, A., Angeletti, M., Aretusi, G., & Mosconi, G. (2015) · Toxicology Research · doi:10.1039/c5tx00314h · Cited by 25
Usui, S., Suzuki, T., Hattori, Y., Etoh, K., Fujieda, H., Nishizuka, M., Imagawa, M., Nakagawa, H., Kohda, K., & Miyata, N. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.01.074 · Cited by 25
Nagasawa, M., Ide, T., Suzuki, M., Tsunoda, M., Akasaka, Y., Okazaki, T., Mochizuki, T., & Murakami, K. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.02.019 · Cited by 27
3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists: Part 1
Epple, R., Russo, R., Azimioara, M. D., Cow, C., Xie, Y., Wang, X., Wityak, J., Karanewsky, D. S., Gerken, A., Iskandar, M., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.055 · Cited by 25
Peroxisome proliferator-activated receptor γ: Its role in metabolic syndrome
Pakala, R., Kuchulakanti, P. K., Rha, S., Cheneau, E. F., Baffour, R., & Waksman, R. (2004) · Cardiovascular Radiation Medicine · doi:10.1016/j.carrad.2004.03.006 · Cited by 27
3D QSAR studies on peroxisome proliferator-activated receptor ? agonists using CoMFA and CoMSIA
Liao, C., Zhou, J., Shi, L. M., Li, Z., Lu, X., & Xie, A. (2004) · Journal of Molecular Modeling · doi:10.1007/s00894-003-0175-4 · Cited by 25
Aryloxazolidinediones: identification of potent orally active PPAR dual α/γ agonists
Desai, R. C., Gratale, D. F., Han, W., Koyama, H., Metzger, E., Lombardo, V. K., MacNaul, K. L., Doebber, T. W., Berger, J. P., Leung, K., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00785-6 · Cited by 25
Honda, A., Kamata, S., Satta, C., Machida, Y., Uchii, K., Terasawa, K., Nemoto, A., Oyama, T., & Ishii, I. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00232 · Cited by 25
Hassan, R. M., Ali, I. H., Abdel‐Maksoud, M. S., Abdallah, H. M. I., Kerdawy, A. M. E., Sciandra, F., & Ghannam, I. A. Y. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202100399 · Cited by 24
Poleni, P.-E., Etienne, S., Velot, É., Netter, P., & Bianchi, A. (2010) · PPAR Research · doi:10.1155/2010/635912 · Cited by 30
“Thus, arachidonic acid metabolites, such as leukotriene B4 for PPAR α, prostaglandin I2 for PPAR β/δ, or 15-deoxyprostaglandin J2 (15d-PGJ2) for PPAR γ [15], are much less effective than pyrixin acid (Wy14643) or fibrates for PPAR α, GW501516 for PPAR β/δ, or thiazolidinediones for PPAR γ [16].”
BackgroundThiazolidinediones and the preservation of β‐cell function, cellular proliferation and apoptosis
Decker, M. W., Hofflich, H., & Elias, A. N. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00745.x · Cited by 24
Therapy of Alzheimer's disease: an update.
Upadhyaya, P., Seth, V., & Ahmad, M. (2010) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp.9000277 · Cited by 29
Zanoni, G., Valli, M., Bendjeddou, L. Z., Porta, A., Bruno, P., & Vidari, G. (2010) · The Journal of Organic Chemistry · doi:10.1021/jo101806m · Cited by 24
Alvaro, D., Carpino, G., Craxì, A., Floreani, A., Moschetta, A., & Invernizzi, P. (2020) · Liver International · doi:10.1111/liv.14627 · Cited by 25
Caron‐Dorval, D., Paquet, P., Paradis, A.-M., Rudkowska, I., Lemieux, S., Couture, P., & Vohl, M. (2008) · Lifestyle Genomics · doi:10.1159/000137555 · Cited by 26
“In the present study, carriers and noncarriers of the PPARa L162V polymorphism after n–3 PUFA supplementation demonstrated a triacylglycerol-lowering effect that was comparable for both genotype groups. Independently of the genotype, the n–3 PUFA supplementation also yielded a decrease in fasting glucose concentration…”
BackgroundKakiuchi-Kiyota, S., Vetro, J. A., Suzuki, S., Varney, M. L., Han, H.-Y., Pontes, M. G. N. E., Pennington, K. L., Arnold, L. L., Singh, R. K., & Cohen, S. M. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.02.028 · Cited by 24
Kumar, R., Mittal, A., & Ramachandran, U. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.081 · Cited by 24
O-Arylmandelic acids as highly selective human PPAR α/γ agonists
Adams, A. D., Hu, Z., Langen, D. J. V., Dadiz, A. C., Elbrecht, A., MacNaul, K. L., Berger, J. P., Zhou, G., Doebber, T. W., Meurer, R. D., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00702-9 · Cited by 24
Filzen, G. F., Bratton, L. D., Cheng, X., Erasga, N. O., Geyer, A. G., Lee, C., Lu, G. H., Pulaski, J., Sorenson, R. J., Unangst, P. C., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.047 · Cited by 24
Han, K. H., & Quehenberger, O. (2000) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(00)00076-1 · Cited by 24
Peroxisome proliferator-activated receptors and acute lung injury
Cuzzocrea, S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.01.008 · Cited by 24
Cardiovascular Drugs Inhibit MMP-9 Activity from Human THP-1 Macrophages
Rival, Y., Benéteau, N., Chapuis, V., Taillandier, T., Lestienne, F., Dupont-Passelaigue, E., Patoiseau, J., Colpaert, F. C., & Junquero, D. C. (2004) · DNA and Cell Biology · doi:10.1089/104454904323090912 · Cited by 24
“Three distinct PPAR subtypes have been identified: PPAR a , PPAR g , and PPAR d (Willson et al ., 2000) with specific distributions and different physiologic functions.”
Forman, B. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200004200 · Cited by 24
Murase, T., Kondo, H., Hase, T., Tokimitsu, I., & Saito, M. (2001) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00162-1 · Cited by 24
Black, N., Ennis, C. N., Young, I. S., Hunter, S. J., Atkinson, A. B., & Bell, P. M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.001 · Cited by 23
Zakaria, Z., Othman, Z. A., Nna, V. U., & Mohamed, M. (2021) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2021.1939387 · Cited by 25
“Natural ligands such as endogenous fatty acids and fatty acid-derived compounds, or synthetic ligands, can activate PPAR a (Willson et al .”
BackgroundSenn, L., Costa, A., Avallone, R., Socała, K., Właź, P., & Biagini, G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108316 · Cited by 23
Suh, Y., Kim, N., Koo, B.-W., Lee, K., Moon, S.-H., Shin, D.-H., Jung, J., Paek, S., Chang, D., Li, F.-N., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8003416 · Cited by 23
Zhou, L., Zhong, Y., Xue, M., Kuang, D., Cao, X., Zhao, Z., Li, H., Xu, Y. F., & Wang, R. (2014) · Chinese Chemical Letters · doi:10.1016/j.cclet.2014.10.008 · Cited by 24
PPAR Medicines and Human Disease: The ABCs of It All
Apostoli, A. J., & Nicol, C. J. B. (2012) · PPAR Research · doi:10.1155/2012/504918 · Cited by 24
“As members of the nuclear receptor superfamily, PPARs contain a ligand-binding domain that recognizes and binds specific PPAR agonists, and a DNA-binding domain that interacts with specific peroxisome proliferator-response elements (PPREs) within the genome [12].”
BackgroundMoreno-Lanceta, A., Medrano-Bosch, M., Simón-Codina, B., Barber-González, M., Jiménez, W., & Melgar-Lesmes, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051452 · Cited by 19
“It has pleiotropic cellular effects, including lipid and glucose metabolism, adipocyte differentiation, cell growth control, and inflammation [19].”
Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
Dohmen, K., Onohara, S.-Y., & Harada, S. (2021) · The Korean Journal of Gastroenterology · doi:10.4166/kjg.2021.092 · Cited by 18
Metadata
- Authors
- Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R.
- Affiliations
- Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-02-01
- Volume
- 43
- Issue
- 4
- Pages
- 527-550
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1977666051
- Cited by
- 1,816
- References
- 216
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 27 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 44 · 2016: 37 · 2015: 60 · 2014: 62 · 2013: 52 · 2012: 92
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- peroxisome proliferator-activated receptors, orphan receptors, drug discovery, receptor agonists, ligands, lipid signaling, nuclear receptors
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hyperlipidemias, Hypertension, Inflammation, Ligands, Models, Molecular, Neoplasms, Nuclear Proteins, Obesity, Transcription Factors, Drug Design, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.